The rationale to target CDK2 for treatment of malignancies includes the indispensable role of CDK2 in proliferation and overexpression of its binding partners, cyclin A or E in several cancers, such as ovary cancer, breast cancer and glioma etc. [3,4,5,6]. The gene discussed is CDK2; the disease is breast cancer.